National and Kapodistrian University of Athens
Προοπτική μελέτη της καρδιακής προσβολής σε ασθενείς με συστηματικό σκληρόδερμα
Abstract
dc:descriptionBackground: Systemic sclerosis (SSc) is a connective tissue disease characterized by widespread vascular lesions and fibrosis of the skin and internal organs. Severe organ involvement occurs within the first 3 years in 45%-55% of the patients with SSc. Severe pulmonary fibrosis, renal crisis and cardiac disease, each carries a similarly bad prognosis, with 5-year survival of ~50%. Cardiac involvement may affect the endocardium, myocardium and pericardium, separately or concomitantly. As a consequence, pericardial effusion, arrhythmias, conduction disease, valvular regurgitation, myocardial ischaemia, myocardial hypertrophy and heart failure may develop. Pulmonary arterial hypertension and renal and lung involvement can also affect cardiac status adversely. Although the frequency of cardiac abnormalities has been identified in autopsy series in more than 80% of the patients, a clinical diagnosis of cardiac involvement is made much less often. Objective: To assess the incidence of cardiac lesions in asymptomatic patients with systemic sclerosis (SSc) of at least 3 year duration, examine the progression of those patients during the next at least 3 years of regular follow-up and search for possible differences of these lesions between the diffuse and the limited type of the disease. Patients and Methods: Sixty nine consecutive patients with SSc (aged 50.8±12.5 years, 63 women) without clinically evident cardiac involvement were evaluated electrocardiographically (ECG and 24-hour Holter recordings) and echocardiographically for cardiac involvement. There were 42 patients with diffuse SSc (aged 49.1±11.4 years, disease duration of 8.5±6.2 years) and 27 patients with limited SSc (aged 53.5±13.7 years, disease duration of 9.1±6.6 years). ‘’Healthy’’ subjects matched 1:1 with patients for age, gender and body mass index served as controls for ECG and Holter recordings. Sixty six of the pts (three patients were lost in follow-up) were reevaluated electrocardiographically (ECG at least annually and 24-hour Holter recordings every three years) and echocardiographically at least annually. Echocardiographic parameters measured included: Left Ventricular Ejection Fraction (LVEF), Pulmonary Arterial Systolic Pressure (PASP) and diastolic dysfunction of Left Ventricular (LV). Spatial QRS-T angle (spQRS-Ta), an established marker of ventricular repolarisation heterogeneity and a strong independent predictor of cardiac morbidity and mortality in the general population, was also obtained. Therapeutic decisions and interventions were made according to the findings. Results: At baseline, among the sixty-nine SSc patients, eight (11.6%) and one (1.5%) had incomplete and complete Right Bundle Branch Block (RBBB), respectively, four (5.8%) had Left Bundle Branch Block (LBBB), four (5.8%) had Left Anterior Hemiblock (LAH) and one (1.5%) had Left ventrticular Hypertrophy (LVH). SpQRS-Ta was wider in SSc (median value 15.6°, interquartile range 10.6–24.3°) than controls (10.5°, 7.3–13.5°, p=0.0001) and was not associated with skin fibrosis extent or specific clinical manifestations and autoantibodies. Twenty-four-hour Holter recordings revealed couplets of ventricular beats in six (Lown class IVa) and non-sustained ventricular tachycardia in five patients (Lown class IVb); spQRS-Ta was wider in those eleven patients with serious ventricular arrhythmia than the remaining patients (24.9°, 14.9–31.3° vs. 14.4°, 9.6–22.3°; p=0.02). Both the patients with limited scleroderma and serious ventricular arrhythmia and those with limited scleroderma and PASP>40mmHg had a wider spQRS-Ta(26.3,19.9-31.3, p=0.02 and 22, 13.5- 27.6, p=0.03, respectively). A spQRS-Ta>19.3° demonstrated 80% sensitivity and 68% specificity (area under the curve 0.81, p=0.02) to predict the presence of non-sustained ventricular tachycardia in Holter monitoring. Severe ventricular arrythmias were associated with elevated PASP>40mmHg (P=0.024), especially in the limited type of the disease (p=0.031). During the next 5.5±2.1 years, 66 of 69 patients were closely monitored in an effort to promptly diagnose and treat any deterioration of cardiac function. There was no cardiac-related death among the 4 patients who died during the follow-up. Three patients developed pericarditis (4.5%) and one hypertrophic cardiomyopathy (1.5%), eight patients (12.1%) developed atrial fibrillation and four patients (6.0%) had a pacemaker implanted. There was an increase in the number of patients with LV diastolic dysfunction (p=0.0026). The patients with disease duration >5 years when entering the study and those with diffuse SSc were more prone to develop diastolic dysfunction of the LV at the end of the study (p=0.02). Although none of the patients developed cardiac insufficiency, there was a significant reduction of the LVEF (p=0.049) at follow-up end. An increase of 4.5% and 5.6% regarding the patients with eosophageal and intestinal involvement was evident at the end of the study, respectively, while a decrease of 6.1% was observed in the number of patients with elevated PASP, probably due to the use of endothelin inhibitors. The spQRS-Ta did not change significantly at follow-up end. Episodes of Lown class>3 (serious arrythmias) were not significantly increased, although there was a significant decrease of the patients without ectopic beats (Lown class 0, p=0.016). The administration of calcium channel blockers and angiotensin-converting-enzyme inhibitors was increased by 12.1% and 3%, respectively. Anti-arrythmics and endothelin inhibitors were added to the treatment when necessary. Conclusion: The results of this prospective cardiological study in a contemporary typical cohort of patients with SSc indicate that late cardiac involvement is common but relatively benign, probably due to the close monitoring and aggressive therapy. PAH should not be the only goal of treatment. Simple screening tests are essential and should be used at least annually in everyday practice. The use of innovative drugs in combination with the conventional cardiological drugs could help in the prevention of serious events.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konstantopoulou, Pinelopi
- Κωνσταντοπούλου, Πηνελόπη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41424